Citation Impact
Citing Papers
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
2018 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2015 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients
2018
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Lp-PLA2- a novel risk factor for high-risk coronary and carotid artery disease
2010
Nitric oxide synthases: regulation and function
2011 Standout
In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE)
2011
Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study
2011
Reprinted Article “A Combination of Statins and Beta-blockers is Independently Associated with a Reduction in the Incidence of Perioperative Mortality and Nonfatal Myocardial Infarction in Patients Undergoing Abdominal Aortic Aneurysm Surgery”
2011
Perioperative Management of Antithrombotic Therapy
2012 Standout
The metabolic syndrome
2010 Standout
Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics
2004
Platelets and acute cerebral infarction
2012 StandoutNobel
Antithrombotic Therapy for VTE Disease
2016 Standout
Extracellular phospholipases in atherosclerosis
2010
Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma
2009
Atherosclerosis: current pathogenesis and therapeutic options
2011 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
The metabolic syndrome
2005 Standout
The immune system in atherosclerosis
2011 Standout
Executive Summary
2012 Standout
Type 2 diabetes
2017 Standout
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians
2011
Prevention of VTE in Nonorthopedic Surgical Patients
2012 Standout
Central venous catheters and upper extremity deep vein thrombosis in medical inpatients: the Medical Inpatients and Thrombosis (MITH) Study
2015
The immune response in atherosclerosis: a double-edged sword
2006 Standout
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
2006
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2009 Standout
Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention
2008
Management of metabolic syndrome: statins
2004
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials
2006
Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: Rationale and design of the DECREASE-IV study
2004
The adhesion molecule P-selectin and cardiovascular disease
2003
Statins, inflammation and kidney disease
2011
The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent
2008
Statin Use Following Intracerebral Hemorrhage
2011
Meglitinide analogues: a review of clinical data focused on recent trials
2006
Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
2003
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Exercise-based cardiac rehabilitation for coronary heart disease
2011 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Determinants of Long-Term Survival After Major Surgery and the Adverse Effect of Postoperative Complications
2005 Standout
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy
2020 Standout
A Combination of Statins and Beta-blockers is Independently Associated with a Reduction in the Incidence of Perioperative Mortality and Nonfatal Myocardial infarction in Patients Undergoing Abdominal Aortic Aneurysm Surgery
2004
High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
2013 Standout
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
2006 Standout
Management of Abdominal Aortic Aneurysms Clinical Practice Guidelines of the European Society for Vascular Surgery
2011 Standout
Statin Use and the Risk of Cholecystectomy in Women
2009
Combination therapy in dyslipidemia: Where are we now?
2014
Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer
2012 Standout
Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
2005 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension
2008
Management of glioblastoma: State of the art and future directions
2020 Standout
Statins for primary prevention of venous thromboembolism
2014
The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation
2009 Standout
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
2001
Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ
2012 Standout
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
2014
PLEIOTROPIC EFFECTS OF STATINS
2004 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2010 Standout
Meglitinide analogues for type 2 diabetes mellitus
2007
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Lipoprotein-Associated Phospholipase A2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study)
2007
The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men
2006
A systematic review and economic evaluation of statins for the prevention of coronary events
2007
The Metabolic Syndrome
2008 Standout
Anticoagulation for people with cancer and central venous catheters
2014
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
2016 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
2020 Standout
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors
2005
Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia
2020 Standout
Hematological findings and complications of COVID ‐19
2020 Standout
Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A 2
2007
Works of C. Abletshauser being referenced
Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index
2001
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: A pooled analysis of double-blind, randomized trials
2006
Reduction of Platelet Activity Markers in Type II Hypercholesterolemic Patients by a HMG-CoA-Reductase Inhibitor
1999
Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus – a randomized study using positron emission tomography
2004
Fluvastatin Slow-Release Lowers Platelet-Activating Factor Acetyl Hydrolase Activity: A Placebo-Controlled Trial in Patients with Type 2 Diabetes
2004
CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency
2011
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL‐profiles
2009
A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study
2010
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
2011
Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia
2001
Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action
2002
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN
2010
Effect of the Angiotensin Receptor Blocker Valsartan on Coronary Microvascular Flow Reserve in Moderately Hypertensive Patients with Stable Coronary Artery Disease
2007
Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype
2001
Effect of the Angiotensin II Receptor Antagonist Valsartan on Lipid Profile and Glucose Metabolism in Patients with Hypertension
2001
Fluvastatin Treatment and Withdrawal: Effects on Endothelial Function
2008